A-share glass-substrate theme remained active; Woge Photonics neared the daily limit and hit a fresh record high. Gebijia, Kaisheng Technology, Three Gorges New Materials, Wufang Optoelectronics and Caihong Shares led gains.

The South Korean won fell to its lowest level against the US dollar (KRW/USD) since March 2009.

Key News 1. Futu Holdings: Starting June 12th, it will suspend trading and fund transfer services for all types of securities, including stocks, in mainland China. Individual Stock News 1. Cambridge Technology (06166.HK) completed the placement of 15.6 million new H shares. 2. Meituan-W (03690.HK): It is proposed to elect Yao Jianhua as an independent non-executive director. 3. Agile Group (01813.HK): Pre-sales in May amounted to RMB 441 million, a year-on-year decrease of 40.2%. 4. Hongyang Real Estate (01996.HK): Cumulative contracted sales for the first five months amounted to RMB 769 million, a year-on-year decrease of 68.87%. 5. Gemdale Properties & Investment (00535.HK): Cumulative contracted sales for the first five months amounted to approximately RMB 3.094 billion, a year-on-year decrease of 25.25%. 6. Lung Fung Group (02290.HK) saw its Hong Kong public offering oversubscribed by 664.92 times, raising net proceeds of approximately HK$599.6 million globally. 7. Dickson Development (00113.HK) released its annual results: profit attributable to equity shareholders was HK$249 million, a year-on-year increase of 25.72%. 8. China Overseas Grand Ocean Group (00081.HK): cumulative contracted sales for the first five months reached RMB15.244 billion, a year-on-year increase of 21.3%. 9. China Overseas Land & Investment (00688.HK): cumulative contracted property sales for the first five months reached approximately RMB103.002 billion, a year-on-year increase of 13.9%. 10. Shijiazhuang Pharmaceutical Group (02005.HK) signed a letter of intent with Xinzheng Heying for cooperation on two improved new drugs, acquiring exclusive global commercialization rights for the two new drugs. 11. Innovent Biologics (01801.HK): The National Medical Products Administration has accepted the new drug application for IBI343 (CLDN18.2 ADC) for the treatment of advanced gastric cancer.